Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

• Status: Unknown status
• Trial end date: 2020-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center, open-label, randomized study. Participants will be assigned to A or B groups with a scale of 1:1 , i.e. infuse study drug followed by Xyntha (group A), or the alternate sequence (group B). All participants who completed the study will enter the Prophylactic Therapy Study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

1. Hemophilia A.

2. FVIII:C <1%. 3）12 and 65 years old.

4）Has received FVIII treatment and the treatment exposure days ≥100. 5）Has bleeding treatment records of at least 3 months before randomization. 6）FVIII inhibitor assay results is negative.

7） Subjects should agree to use an adequate method of contraception during the study.

8）Understood and Signed an informed consent form. 9）Has not received an treatment of any FVIII within 4 days before the first dose.

10）Non-bleeding state.

Exclusion Criteria:

1. Has a history or family history of blood coagulation factor VIII inhibitor.

2. Has other coagulation dysfunction diseases in addition to hemophilia A.

3. HIV positive.

4. Plan to receive surgery during the trial.

5. Has used immunomodulator within one weeks before the first dose，and less than 7 half-life periods.

6. Known to be allergic to experimental drugs or any excipients.

7. Severe anemia and need blood transfusion.

8. Serious liver or kidney damage.

9. Serious heart disease.

10. Uncontrollable hypertension.

11. Has participated in other clinical studies within one month before the first dose.

12. The researchers believe that it is not suitable for participants.